Imatinib
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DRUG-IMATINIB |
|---|---|
| Tipo | Fármaco |
| Aliaces | GleevecGlivecimatinib genéricoІматиніб |
| Situación | reviewed 2026-04-25 | pending_clinical_signoff |
| Enfermedades | DIS-CML DIS-GIST DIS-MELANOMA |
| Fuentes | SRC-ELN-CML-2020 SRC-IRIS-OBRIEN-2003 SRC-NCCN-MPN-2025 |
Datos sobre drogas
| Clase | BCR-ABL1 / KIT / PDGFR inhibidor de tirosina-quinasa (1a generación) |
|---|---|
| Mecanismo | Selective TKI of BCR-ABL1, KIT, PDGFR-α/β. Founder of the targeted CML era. Standard CML 1L for low-risk, comorbid, or cost-constrained patients. |
| Dosificación típica | CML chronic phase: 400 mg PO once daily with food + large glass of water. Ph+ ALL: 600-800 mg daily. Take with meal to reduce GI toxicity. |
| Ucrania registrada | Cierto |
| NSZU reembolsado | Cierto |
| Ucrania verificada por última vez | 2026-04-27 |
Notas
Standard 1L for low-risk Sokal/EUTOS CML, elderly, or in cost-constrained settings (generics widely available, НСЗУ-reimbursed in Ukraine). 2nd-gen TKIs (dasatinib, nilotinib, bosutinib) achieve faster deep molecular response but no consistent OS benefit — ELN 2020 leaves choice to comorbidity matrix. Take with food + water.
Utilizado por
Esquema terapéutico
REG-IMATINIB-CML- Imatinib (CML chronic phase 1L)REG-IMATINIB-GIST-1L- Imatinib (GIST avanzado/metastásico 1L; KIT/PDGFRA sensible a imatinib)REG-IMATINIB-KIT-MELANOMA- Imatinib (mucosa mutante KIT/melanoma acral)